
Samsung Biologics Co Ltd
KRX:207940

Intrinsic Value
The intrinsic value of one
Samsung Biologics Co Ltd
stock under the Base Case scenario is
546 294.0838
KRW.
Compared to the current market price of 999 999.9999 KRW,
Samsung Biologics Co Ltd
is
Overvalued by 45%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Samsung Biologics Co Ltd
Fundamental Analysis


Revenue & Expenses Breakdown
Samsung Biologics Co Ltd
Balance Sheet Decomposition
Samsung Biologics Co Ltd
Current Assets | 4.8T |
Cash & Short-Term Investments | 946.8B |
Receivables | 1.1T |
Other Current Assets | 2.8T |
Non-Current Assets | 11.2T |
Long-Term Investments | 53B |
PP&E | 5.1T |
Intangibles | 5.7T |
Other Non-Current Assets | 334.3B |
Free Cash Flow Analysis
Samsung Biologics Co Ltd
KRW | |
Free Cash Flow | KRW |
Earnings Waterfall
Samsung Biologics Co Ltd
Revenue
|
4.5T
KRW
|
Cost of Revenue
|
-2.3T
KRW
|
Gross Profit
|
2.3T
KRW
|
Operating Expenses
|
-970.8B
KRW
|
Operating Income
|
1.3T
KRW
|
Other Expenses
|
-236.7B
KRW
|
Net Income
|
1.1T
KRW
|
Profitability Score
Profitability Due Diligence
Samsung Biologics Co Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

Score
Samsung Biologics Co Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Samsung Biologics Co Ltd's solvency score is 86/100. The higher the solvency score, the more solvent the company is.

Score
Samsung Biologics Co Ltd's solvency score is 86/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Samsung Biologics Co Ltd
According to Wall Street analysts, the average 1-year price target for
Samsung Biologics Co Ltd
is 1 335 736.3636 KRW
with a low forecast of 1 161 500 KRW and a high forecast of 1 680 000 KRW.
Dividends
Current shareholder yield for Samsung Biologics Co Ltd is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
Samsung Biologics Co Ltd
stock under the Base Case scenario is
546 294.0838
KRW.
Compared to the current market price of 999 999.9999 KRW,
Samsung Biologics Co Ltd
is
Overvalued by 45%.